In:
FEBS Letters, Wiley, Vol. 591, No. 1 ( 2017-01), p. 129-136
Abstract:
Glial fibrillary acidic protein ( GFAP ), expressed in peri‐islet Schwann cells, is a novel target for the treatment of type 1 diabetes mellitus (T1 DM ). We designed a GFAP immune‐tolerizing vaccine that successfully suppresses hyperglycemia and enhances C peptide secretion. The GFAP vaccine significantly prevented T cell infiltration into pancreatic islets. Moreover, after GFAP vaccination, naïve T‐cell differentiation shifted from a cytotoxic Th1‐ to a Th2‐biased humoral response. These results indicate that as a novel target, GFAP reliably predicts the development of T1 DM , and that the GFAP vaccine successfully delays the progression of T1 DM by regulating T‐cell differentiation.
Type of Medium:
Online Resource
ISSN:
0014-5793
,
1873-3468
DOI:
10.1002/feb2.2017.591.issue-1
DOI:
10.1002/1873-3468.12511
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1460391-3
SSG:
12